Clinical trials: Coronavirus 2019
COVID-19
Mesenchymal Stem Cell Infusion for COVID-19 Infection
Since the outbreak of coronavirusdisease2019(COVID-19), many researchers in China have carried out/published clinical trials on treatment based on Western medicine, traditional Chinese medicine or a combination of the two.
- Trial name
- NCT04444271
- Testing
- Mesenchymal stem cells
- Where
- Pakistan
- Volunteers
- 20 people
- Sponsor
- Dr. Zaineb Akram
Covid19
Early Detection of COVID-19 Using Breath Analysis
EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY
- Trial name
- COVID-19 (NCT04602884)
- Testing
- Breath biopsy sampling using the ReCIVA Breath Sampler
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
COVID-19
Interferon Beta 1a in Hospitalized COVID-19 Patients
The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical…
- Trial name
- IB1aIC (NCT04350671)
- Testing
- Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Post COVID-19 Diffuse Lung Disease
Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease
A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of these patients continue to have considerable respiratory symptoms or persistent hypoxemia.
- Trial name
- COLDSTER (NCT04657484)
- Testing
- Medium dose prednisolone, Low dose prednisolone
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
Coronavirus Infection, Critical Illness
Clinical Characteristics of Critically Ill Patients With COVID-19
Critically ill patients with COVID-19 have hospitalized in an ICU due to the closer monitoring and therapy. In fact, ICU admissions are dependent on the severity of illness and the ICU capacity of the health-care system.
- Conditions
- Coronavirus Infection, Critical Illness, Characteristics Disease
- Trial name
- NCT04413435
- Testing
- File Scanning
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people
- Sponsor
- Nevsehir Public Hospital
Coronavirus Disease 2019
Neurologic Manifestations of COVID-19
This study will determine the neurological profile and predictors of outcomes in patients with COVID-19 disease in the Philippines.
- Trial name
- CORONA (NCT04386083)
- Where
- Philippines
- Volunteers
- 1,342 people
- Sponsor
- University of the Philippines
Severe Acute Respiratory Syndrome Coronavirus 2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
- Trial name
- NCT04360486
- Testing
- Anti-Sars-CoV-2 Convalescent Plasma
- Where
- 38 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Safety and Effectiveness of an Immunobiological Drug in CoViD-19
The aims of this study is to analyze the efficacy and safety of a passive immunotherapy strategy using hyperimmune equine serum known as Anti-SARS-CoV-2 elaborated by the National Institute for the Production of Biologicals…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Covid19
- Trial name
- INPB001 (NCT04913779)
- Testing
- Anti-SARS-CoV-2
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran
COVID-19
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
This is a Phase 3 study to assess the efficacy about therapeutic effect of inhaled CT-P63 and CT-P66 combination therapy to symptomatic patiemts with COVID-19 and overall safety.
- Trial name
- NCT05224856
- Sponsor
- Celltrion
MRSA Bloodstream Infection, MRSA Bacteremia
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)…
- Conditions
- MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
- Trial name
- NCT04597242
- Testing
- Exebacase
- Where
- 2 sites in United States
- Sponsor
- ContraFect
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
COVID-19, Coronavirus Disease 2019
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia.
- Conditions
- COVID-19, Coronavirus Disease 2019, Covid19, COVID-19 Pneumonia
- Trial name
- NCT04390217
- Testing
- LB1148
- Sponsor
- Leading BioSciences, Inc
COVID-19
Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease
The global COVID-19 pandemic has caused unprecedented strain on health care services around the world.The absence of specific anti-viral medications to treat the underlying infection led to a proliferation of clinical studies and…
- Trial name
- DEFEAT-COVID (NCT05007678)
- Testing
- leflunomide
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Ashford and St. Peter's Hospitals NHS Trust
COVID19
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
- Trial name
- TCInpatient (NCT04338126)
- Testing
- Tranexamic acid
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19.
- Conditions
- Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT04665115
- Testing
- Ibrutinib, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Academic and Community Cancer Research United
COVID-19
Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia
This retrospective monocentric study compares 2 ventilatory support strategies on outcomes (length of stay, intubation, mortality) in patients admitted in Intensive Care Unit with Covid-19 related pneumonia : invasive strategy…
- Trial name
- STRATIC (NCT04799691)
- Testing
- Invasive ventilation strategy, Non-invasive ventilation strategies
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Cardiovascular Diseases, COVID
Cardiovascular Manifestations of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first reports of COVID-19 came from Wuhan, China in December of 2019.
- Trial name
- NCT04335630
- Testing
- Electrocardiogram, telemetry, echocardiogram, laboratory values
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Memorial Hermann Health System